BOULDER, CO / ACCESSWIRE / August 15, 2024 / Encision Inc. (OTC PINK:ECIA), a medical device company owning patented Active Electrode Monitoring (AEM®) Technology that prevents dangerous radiant energy burns in minimally invasive surgery, today announced financial results for its fiscal 2025 first quarter that ended June 30, 2024.
The Company posted quarterly product net revenue of $1.59 million and service net revenue of $39 thousand, or total net revenue of $1.63 million for a quarterly net income of $22 thousand, or $0.00 per diluted share. These results compare to product net revenue of $1.61 million and service net revenue of $40 thousand, or total net revenue of $1.65 million for a quarterly net loss of $140 thousand, or $(0.01) per diluted share, in the year-ago quarter. Gross margin on product net revenue was 58% in the fiscal 2025 first quarter and 52% in the fiscal 2024 first quarter. Gross margin increased in the current year's first quarter compared to last year's first quarter due principally to higher operating efficiencies and increased selling prices.
"It is very encouraging to be able to share positive results for Encision's efforts" said Gregory Trudel, President and CEO of Encision Inc. "The fiscal 2025 first quarter presented significant challenges for Encision but we are beginning to reap the benefit from our investment in our sales channel and technology. We continue working to create service revenue streams with new partners and opportunities to collaborate on our foundational technologies."
Encision Inc. designs and markets a portfolio of high-performance surgical instrumentation that delivers advances in patient safety with AEM technology, surgical performance, and value to hospitals across a broad range of minimally invasive surgical procedures. Based in Boulder, Colorado, the company pioneered the development and deployment of Active Electrode Monitoring, AEM technology, to eliminate dangerous stray energy burns during minimally invasive procedures. For additional information about all our products, please visit www.encision.com.
In accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, the Company notes that statements in this press release and elsewhere that look forward in time, which include everything other than historical information, involve risks and uncertainties that may cause actual results to differ materially from those indicated by the forward-looking statements. Factors that could cause the Company's actual results to differ materially include, among others, its ability to develop new or enhanced products and have such products accepted in the market, its ability to increase net sales through the Company's distribution channels, its ability to compete successfully against other manufacturers of surgical instruments, insufficient quantity of new account conversions, insufficient cash to fund operations, delay in developing new products and receiving FDA approval for such new products and other factors discussed in the Company's filings with the Securities and Exchange Commission. Readers are encouraged to review the risk factors and other disclosures appearing in the Company's Annual Report on Form 10-K for the year ended March 31, 2024 and subsequent filings with the Securities and Exchange Commission. We do not undertake any obligation to update publicly any forward-looking statements, whether as a result of the receipt of new information, future events, or otherwise.
CONTACT: Mala Ray, Encision Inc., 303-444-2600, This email address is being protected from spambots. You need JavaScript enabled to view it.
Encision Inc.
Unaudited Condensed Statements of Operations
in thousands, except per share information)
| Three Months Ended |
| |||||
| June 30, 2024 |
|
| June 30, 2023 |
| ||
Product revenue | $ | 1,592 |
|
| $ | 1,613 |
|
Service revenue |
| 39 |
|
|
| 40 |
|
Total revenue |
| 1,631 |
|
|
| 1,653 |
|
|
|
|
|
|
|
| |
Product cost of revenue |
| 668 |
|
|
| 770 |
|
Service cost of revenue |
| 20 |
|
|
| 20 |
|
Total cost of revenue |
| 688 |
|
|
| 790 |
|
|
|
|
|
|
|
| |
Gross profit |
| 943 |
|
|
| 863 |
|
Operating expenses: |
|
|
|
|
|
|
|
Sales and marketing |
| 424 |
|
|
| 433 |
|
General and administrative |
| 352 |
|
|
| 389 |
|
Research and development |
| 139 |
|
|
| 169 |
|
Total operating expenses |
| 915 |
|
|
| 991 |
|
Operating income (loss) |
| 28 |
|
|
| (128 | ) |
Interest expense and other income, net |
| (6 | ) |
|
| (12 | ) |
Income (loss) before provision for income taxes |
| 22 |
|
|
| (140 | ) |
Provision for income taxes |
| -- |
|
|
| -- |
|
Net income (loss) | $ | 22 |
|
| $ | (140 | ) |
Net income (loss) per share-basic and diluted | $ | 0.00 |
|
| $ | (0.01 | ) |
Weighted average number of basic shares |
| 11,875 |
|
|
| 11,770 |
|
Weighted average number of diluted shares |
| 11,907 |
|
|
| 11,770 |
|
Encision Inc.
Unaudited Condensed Balance Sheets
(in thousands)
|
| March 31, 2024 |
| March 31, 2024 |
ASSETS |
|
|
|
|
Cash |
| $270 |
| $43 |
Accounts receivable |
| 817 |
| 891 |
Inventories |
| 1,318 |
| 1,402 |
Prepaid expenses and other assets |
| 108 |
| 90 |
Total current assets |
| 2,513 |
| 2,426 |
Equipment, net |
| 252 |
| 254 |
Right of use asset |
| 819 |
| 901 |
Patents, net |
| 167 |
| 164 |
Other assets |
| 69 |
| 66 |
Total assets |
| $ 3,820 |
| $ 3,811 |
LIABILITIES AND SHAREHOLDERS' EQUITY |
|
|
|
|
Accounts payable |
| $ 270 |
| $ 346 |
Secured notes |
| 41 |
| 42 |
Line of credit |
| 299 |
| 157 |
Accrued compensation |
| 210 |
| 185 |
Other accrued liabilities |
| 100 |
| 120 |
Accrued lease liability |
| 424 |
| 370 |
Total current liabilities |
| 1,344 |
| 1,220 |
Secured notes |
| 58 |
| 67 |
Accrued lease liability |
| 558 |
| 697 |
Unsecured promissory note |
| -- |
| -- |
Total liabilities |
| 1,960 |
| 1,984 |
Common stock and additional paid-in capital |
| 24,383 |
| 24,372 |
Accumulated (deficit) |
| (22,523) |
| (22,545) |
Total shareholders' equity |
| 1,860 |
| 1,827 |
Total liabilities and shareholders' equity |
| $ 3,820 |
| $ 3,811 |
Encision Inc.
Unaudited Condensed Statements of Cash Flows
(in thousands)
|
| Three Months Ended |
| ||
|
| June 30, 2023 |
| June 30, 2023 | |
Operating activities: |
|
|
|
| |
Net income (loss) |
| $ 22 |
| $ (140) | |
Adjustments to reconcile net income (loss) to cash generated by (used in) operating activities: |
|
|
|
| |
Depreciation and amortization |
| 19 |
| 22 | |
Share-based compensation expense |
| 12 |
| 13 | |
Provision for inventory obsolescence, net |
| 1 |
| 9 | |
Changes in operating assets and liabilities: |
|
|
|
| |
Right of use asset, net |
| (3) |
| (12) | |
Accounts receivable |
| 75 |
| 8 | |
Inventories |
| 83 |
| 23 | |
Prepaid expenses and other assets |
| (22) |
| 24 | |
Accounts payable |
| (76) |
| 24 | |
Accrued compensation and other accrued liabilities |
| 7 |
| (17) | |
Net cash (used in) provided by operating activities |
| 118 |
| (46) | |
|
|
|
|
| |
Investing activities: |
|
|
|
| |
Acquisition of property and equipment |
| (14) |
| -- | |
Patent costs |
| (6) |
| (1) | |
Net cash (used in) investing activities |
| (20) |
| (1) | |
|
|
|
|
| |
Financing activities: |
|
|
|
| |
Proceeds from (paydown of) secured notes |
| 131 |
| (11) | |
(Payments) from exercise of stock options |
| (1) |
| -- | |
Net cash provided by (used in) financing activities |
| 130 |
| (11) | |
|
|
|
|
| |
Net increase (decrease) in cash |
| 228 |
| (58) | |
Cash, beginning of period |
| 42 |
| 189 | |
Cash, end of period |
| $270 |
| $131 | |
|
|
|
|
|
|
| Last Trade: | US$0.39 |
| Daily Change: | 0.04 11.43 |
| Daily Volume: | 6,500 |
| Market Cap: | US$4.630M |
November 15, 2024 August 21, 2024 July 15, 2024 February 14, 2024 November 14, 2023 | |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
